Chikungunya virus: new risk to transfusion safety in the <scp>A</scp>mericas

Petersen, Lyle R.; Epstein, Jay S.

doi:10.1111/trf.12790

Cited by 30 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, despite a relatively high occurrence of this agent in the general population, no transfusion‐transmitted cases have been reported globally either with or without PRT treatment. It has been suggested that the lack of transfusion‐transmitted cases could be due to the short period of viremia and the difficulty of diagnosis during large outbreaks . Although the amount of virus required for transfusion transmission is not known, this suggests that high levels of viremia may be required to transmit virus by transfusion, a probability that may be further reduced with even modest reduction in infectious titer of these agents.…”

Section: Discussionmentioning

confidence: 99%

The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

et al. 2014

View full text Add to dashboard Cite

Our study demonstrates that treatment of PLT concentrates with PRT (Mirasol) reduces the infectious levels of RRV, BFV, and MVEV. The relevance of the level of reduction required to prevent disease transmission by transfusion has not been fully defined and requires further investigation. In the face of a changing climate, with its associated threat to blood safety, PRT represents a proactive approach for maintaining blood safety.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Some transplant patients may require transfusion with large volumes of plasma, resulting in multiple donor exposures with an increased risk of transfusion‐transmitted infection (TTI). These risks may arise from pathogens that escape detection during the window period, undetectable pathogens due to low copy number, or emerging pathogens for which no tests are available . Treatment of plasma with amotosalen and UVA light inactivates a broad spectrum of blood‐borne pathogens providing a means to mitigate the risk of TTI …”

mentioning

confidence: 99%

Comparative effectiveness of plasma prepared with amotosalen‐UVA pathogen inactivation and conventional plasma for support of liver transplantation

Cinqualbre

Kientz²,

Remy³

et al. 2015

Transfusion

View full text Add to dashboard Cite

BACKGROUND Liver transplant may require large‐volume plasma transfusion with increased risk of transfusion‐transmitted infection (TTI). Pathogen inactivation of plasma with amotosalen‐UVA offers the potential to mitigate TTI risk. STUDY DESIGN AND METHODS A retrospective cohort design was used to compare the therapeutic efficacy and key safety outcomes for liver transplants supported with quarantine plasma (Q‐FFP [reference]) or amotosalen‐UVA plasma (IBS plasma [test]). The outcomes evaluated were volume of plasma, the numbers of red blood cell (RBC) components, and the total dose of platelets (PLTs) transfused during and 7 days after transplant. The safety outcomes were acute hepatic artery thrombosis (HAT) and mortality. RESULTS Transplantation and transfusion records for 212 Q‐FFP transplants and 215 IBS plasma transplants were reviewed. Not all transplants required plasma; 161 received Q‐FFP and 174 received IBS plasma. Among the transplants that required plasma, there were significant differences in median values between cohorts for delay to transplantation (p = 0.002), model end‐stage liver disease score (p < 0.001), pretransplant hematocrit (p = 0.006), and graft cold perfusion time (p = 0.033). The median volumes of plasma transfused were not different for test and reference (2.160 L vs. 1.969 L, p = 0.292). Transplants in the test cohort required a mean of 3.7% more RBC components (p = 0.767) and on average a 16.5% increase in total PLT dose (p = 0.518). No significant differences were observed for the frequency of acute HAT or mortality. CONCLUSION In this retrospective study, IBS plasma provided therapeutic support of liver transplant not different from Q‐FFP.

show abstract

“…This is another mosquito-borne pathogen that could potentially pose a risk to transfusion safety, although to date reports of transfusionrelated transmission of this virus are rare [33]. A mutated form of the Chikungunya virus has been responsible for several epidemics in the past decade, spreading to the Reunion Islands in the Indian Ocean (2005), Italy (2007) and the Caribbean area (2012/2013) [34][35][36]. The virus may be detected in blood donors by NAT, which will help to reduce the level of transmission risk [35].…”

Section: Chikungunya Virusmentioning

confidence: 99%

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

et al. 2016

View full text Add to dashboard Cite

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community. Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations of pathogens do not necessarily imply a low level of risk for the patient and so the overall challenge of minimising risk remains. This review aims to discuss the variable level of pathogenic risk and describes the current screening methods used to prevent/detect the presence of pathogens in blood/plasma-derived products

show abstract

Chikungunya virus: new risk to transfusion safety in the Americas

Cited by 30 publications

References 41 publications

The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

Comparative effectiveness of plasma prepared with amotosalen‐UVA pathogen inactivation and conventional plasma for support of liver transplantation

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

Contact Info

Product

Resources

About